KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Operations: 2009-2024

Historic Cash from Operations for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $58.7 million.

  • Emergent BioSolutions' Cash from Operations fell 101.50% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 92.38%. This contributed to the annual value of $58.7 million for FY2024, which is 128.45% up from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Cash from Operations is $58.7 million, which was up 128.45% from -$206.3 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Cash from Operations high stood at $536.9 million for FY2020, and its period low was -$206.3 million during FY2023.
  • Its 3-year average for Cash from Operations is -$60.6 million, with a median of -$34.1 million in 2022.
  • Per our database at Business Quant, Emergent BioSolutions' Cash from Operations soared by 185.59% in 2020 and then crashed by 504.99% in 2023.
  • Emergent BioSolutions' Cash from Operations (Yearly) stood at $536.9 million in 2020, then plummeted by 40.36% to $320.2 million in 2021, then slumped by 110.65% to -$34.1 million in 2022, then slumped by 504.99% to -$206.3 million in 2023, then soared by 128.45% to $58.7 million in 2024.